vs
Side-by-side financial comparison of Insulet Corporation (PODD) and Teradyne (TER). Click either name above to swap in a different company.
Teradyne is the larger business by last-quarter revenue ($1.3B vs $783.7M, roughly 1.6× Insulet Corporation). Teradyne runs the higher net margin — 31.1% vs 13.0%, a 18.1% gap on every dollar of revenue. On growth, Teradyne posted the faster year-over-year revenue change (87.0% vs 31.2%). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 32.6%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
Teradyne, Inc. is an American automatic test equipment (ATE) designer and manufacturer based in North Reading, Massachusetts. Its high-profile customers include Samsung, Qualcomm, Intel, Analog Devices, Texas Instruments and IBM.
PODD vs TER — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $783.7M | $1.3B |
| Net Profit | $101.6M | $398.9M |
| Gross Margin | 72.6% | 60.9% |
| Operating Margin | 18.7% | 36.9% |
| Net Margin | 13.0% | 31.1% |
| Revenue YoY | 31.2% | 87.0% |
| Net Profit YoY | 0.9% | — |
| EPS (diluted) | $1.42 | $2.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.3B | ||
| Q4 25 | $783.7M | $1.1B | ||
| Q3 25 | $706.3M | $769.2M | ||
| Q2 25 | $649.1M | $651.8M | ||
| Q1 25 | $569.0M | $685.7M | ||
| Q4 24 | $597.5M | $752.9M | ||
| Q3 24 | $543.9M | $737.3M | ||
| Q2 24 | $488.5M | $729.9M |
| Q1 26 | — | $398.9M | ||
| Q4 25 | $101.6M | $257.2M | ||
| Q3 25 | $87.6M | $119.6M | ||
| Q2 25 | $22.5M | $78.4M | ||
| Q1 25 | $35.4M | $98.9M | ||
| Q4 24 | $100.7M | $146.3M | ||
| Q3 24 | $77.5M | $145.6M | ||
| Q2 24 | $188.6M | $186.3M |
| Q1 26 | — | 60.9% | ||
| Q4 25 | 72.6% | 57.2% | ||
| Q3 25 | 72.2% | 58.4% | ||
| Q2 25 | 69.7% | 57.2% | ||
| Q1 25 | 71.9% | 60.6% | ||
| Q4 24 | 72.1% | 59.4% | ||
| Q3 24 | 69.3% | 59.2% | ||
| Q2 24 | 67.7% | 58.3% |
| Q1 26 | — | 36.9% | ||
| Q4 25 | 18.7% | 27.1% | ||
| Q3 25 | 16.7% | 18.9% | ||
| Q2 25 | 18.7% | 13.9% | ||
| Q1 25 | 15.6% | 17.6% | ||
| Q4 24 | 18.3% | 20.4% | ||
| Q3 24 | 16.2% | 20.6% | ||
| Q2 24 | 11.2% | 28.8% |
| Q1 26 | — | 31.1% | ||
| Q4 25 | 13.0% | 23.7% | ||
| Q3 25 | 12.4% | 15.5% | ||
| Q2 25 | 3.5% | 12.0% | ||
| Q1 25 | 6.2% | 14.4% | ||
| Q4 24 | 16.9% | 19.4% | ||
| Q3 24 | 14.2% | 19.8% | ||
| Q2 24 | 38.6% | 25.5% |
| Q1 26 | — | $2.53 | ||
| Q4 25 | $1.42 | $1.62 | ||
| Q3 25 | $1.24 | $0.75 | ||
| Q2 25 | $0.32 | $0.49 | ||
| Q1 25 | $0.50 | $0.61 | ||
| Q4 24 | $1.38 | $0.89 | ||
| Q3 24 | $1.08 | $0.89 | ||
| Q2 24 | $2.59 | $1.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $241.9M |
| Total DebtLower is stronger | $930.8M | $0 |
| Stockholders' EquityBook value | $1.5B | — |
| Total Assets | $3.2B | $4.4B |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $241.9M | ||
| Q4 25 | — | $293.8M | ||
| Q3 25 | — | $272.7M | ||
| Q2 25 | — | $339.3M | ||
| Q1 25 | — | $475.6M | ||
| Q4 24 | — | $553.4M | ||
| Q3 24 | — | $510.0M | ||
| Q2 24 | — | $421.9M |
| Q1 26 | — | $0 | ||
| Q4 25 | $930.8M | — | ||
| Q3 25 | $934.9M | — | ||
| Q2 25 | $939.0M | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $2.8B | ||
| Q3 25 | $1.4B | $2.7B | ||
| Q2 25 | $1.5B | $2.8B | ||
| Q1 25 | $1.3B | $2.8B | ||
| Q4 24 | $1.2B | $2.8B | ||
| Q3 24 | $1.1B | $2.9B | ||
| Q2 24 | $998.4M | $2.7B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $3.2B | $4.2B | ||
| Q3 25 | $3.0B | $4.0B | ||
| Q2 25 | $3.5B | $3.8B | ||
| Q1 25 | $3.5B | $3.7B | ||
| Q4 24 | $3.1B | $3.7B | ||
| Q3 24 | $3.0B | $3.8B | ||
| Q2 24 | $2.9B | $3.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.64× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.3M | $265.1M |
| Free Cash FlowOCF − Capex | $48.2M | — |
| FCF MarginFCF / Revenue | 6.2% | — |
| Capex IntensityCapex / Revenue | 17.2% | — |
| Cash ConversionOCF / Net Profit | 1.80× | 0.66× |
| TTM Free Cash FlowTrailing 4 quarters | $377.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $265.1M | ||
| Q4 25 | $183.3M | $281.6M | ||
| Q3 25 | $125.7M | $49.0M | ||
| Q2 25 | $196.5M | $182.1M | ||
| Q1 25 | $63.8M | $161.6M | ||
| Q4 24 | $147.7M | $282.6M | ||
| Q3 24 | $98.5M | $166.3M | ||
| Q2 24 | $96.5M | $216.1M |
| Q1 26 | — | — | ||
| Q4 25 | $48.2M | $218.8M | ||
| Q3 25 | $100.1M | $2.4M | ||
| Q2 25 | $177.9M | $131.7M | ||
| Q1 25 | $51.5M | $97.6M | ||
| Q4 24 | $94.1M | $225.2M | ||
| Q3 24 | $71.8M | $114.4M | ||
| Q2 24 | $74.0M | $171.2M |
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 20.2% | ||
| Q3 25 | 14.2% | 0.3% | ||
| Q2 25 | 27.4% | 20.2% | ||
| Q1 25 | 9.1% | 14.2% | ||
| Q4 24 | 15.7% | 29.9% | ||
| Q3 24 | 13.2% | 15.5% | ||
| Q2 24 | 15.1% | 23.5% |
| Q1 26 | — | — | ||
| Q4 25 | 17.2% | 5.8% | ||
| Q3 25 | 3.6% | 6.1% | ||
| Q2 25 | 2.9% | 7.7% | ||
| Q1 25 | 2.2% | 9.3% | ||
| Q4 24 | 9.0% | 7.6% | ||
| Q3 24 | 4.9% | 7.0% | ||
| Q2 24 | 4.6% | 6.1% |
| Q1 26 | — | 0.66× | ||
| Q4 25 | 1.80× | 1.09× | ||
| Q3 25 | 1.43× | 0.41× | ||
| Q2 25 | 8.73× | 2.32× | ||
| Q1 25 | 1.80× | 1.63× | ||
| Q4 24 | 1.47× | 1.93× | ||
| Q3 24 | 1.27× | 1.14× | ||
| Q2 24 | 0.51× | 1.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
TER
Segment breakdown not available.
